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Recalcitrant pemphigus vulgaris: aseptic meningitis
associated with intravenous immunoglobulin therapy and
successful treatment with rituximab
Dear Sir,
We report the case of a 26-year-old woman with a
5-year history of a severe and recalcitrant pemphigus
vulgaris (PV) (Fig. 1). During this period, the patient
was treated with prednisolone, first combined with
azathioprine and later with mycophenolate mofetil, but
without complete response and always worsening when
prednisolone tapering was attempted. In this setting, she
was treated with intravenous immunoglobulin (IVIG)
(2 g/kg over three days) in combination with predniso-
lone (40 mg/d). On the third day of IVIG, she presented
with severe headache, nuchal rigidity, photophobia, and
nausea. Neurological examination was otherwise normal
as was the brain computed tomography scan. Lumbar
puncture was performed, and the cerebrospinal fluid pre-
dominantly showed a raised white cell lymphocyte count
(80/ll) with normal glucose and protein contents. Cere-
brospinal fluid culture and polymerase chain reaction for
common viruses were both negative. These findings sup-
ported the diagnosis of aseptic meningitis secondary to
immunoglobulin infusion. She recovered over the next
48 hours without any medication, and she was dis-
charged after four days.
The PV continued to worsen with numerous active
lesions mostly on the scalp, face, back, and oral mucosa.
Cyclosporine in association with prednisolone and myco-
phenolate mofetil had no benefit. Finally, rituximab
375 mg/m2 IV weekly, over four consecutive weeks, was
tried. After the second infusion, lesions began to heal,
with complete re-epithelization two months after treat-
ment. No relevant side effects were reported. After one -
year, the patient is doing well, without lesions (Fig. 2).
It should be noted in this case the occurrence of aseptic
meningitis as a serious side effect of treatment with IVIG
and the good response to rituximab. In fact, IVIG therapy
is widely used in autoimmune diseases and usually recog-
nized as a safe biologic agent.1 Aseptic meningitis is one
of the uncommon severe adverse reactions of IVIG ther-
apy.2 The incidence ranges from 11% to 17%.3 The
mechanism for IVIG-induced aseptic meningitis is not
well understood. Studies showed that severe adverse
events might be minimized by enforcing a slow adminis-
tration rate and adequate hydration.2
Rituximab results in the depletion of normal as well as
malignant B cells, leading to investigation of its use in
autoimmune disorders, particularly in the treatment of
systemic lupus erythematosus4 and rheumatoid arthritis.5
Although there have been no randomized controlled trials
of rituximab in dermatologic disease, case reports
describe its use in PV, paraneoplastic pemphigus,
epidermolysis bullosa acquisita, cutaneous B-cell
lymphoma, dermatomyositis, graft-versus-host disease,
Wegener’s granulomatosis, microscopic polyangiitis, cryo-
globulinemic vasculitis, and Churg–Strauss syndrome.6 501
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Figure 1 (a) and (b) Pemphigus vulgaris: lesions on the face
despite combination therapy
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The successful use of rituximab in over 30 cases of resis-
tant PV has been reported.6–8 In most cases, the response
to rituximab was rapid, with improvement noted within
the first 2–6 weeks, and it was well tolerated. However,
four serious infections were reported, including pneumo-
nia, a relapse of septic arthritis of the hip, sepsis, and
fatal Pneumocystis carinii pneumonia.6 This case confirms
and underlines the importance of rituximab in the treat-
ment of recalcitrant PV.
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Apocrine hidrocystoma on the penis of a 40-year-old
man
A 40-year-old man was referred to our department for
evaluation of an asymptomatic lesion over his penis for
the last four years, which had increased in size over the
last months. His past medical history was irrelevant. He
referred no symptoms, and he denied traumatism and
risky or vigorous sexual activities.
Physical examination revealed a painless, well-defined,
serpinginous mass measuring 3 · 0.5 cm over his right
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Figure 2 (a) and (b) After treatment with rituximab
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